Effect of cirrhosis at baseline on the outcome of type 1 autoimmune hepatitis

Material and methods. With the aim of analyzing the influence of presence of cirrhosis at baseline on the outcome, we revised the evolution of a cohort of patients with type 1 autoimmune hepatitis, prospectively followed at a single hospital. 139 patients (113 females, 26 males), median age 45.7 years, interquartile range 13-59 years, were followed-up for a median period of 58 months (interquartile range 27-106).Results. At baseline, 55 patients had cirrhosis and they were significantly older, had lower prothrombin activity and serum albumin than patients without cirrhosis. In contrast, patients without cirrhosis had significantly higher bilirubin, AST and ALT levels at diagnosis time. There was no significant difference in the follow-up time between patients with and without cirrhosis at baseline and either in the percentage of patients receiving immunosupresor treatment (80 vs. 91%, respectively) or in the response to therapy (complete response in 82 vs. 95%, respectively). However, patients with cirrhosis had a significantly lower probability of remaining free of cirrhosis complications (49.1% at 102 months, 95%CI, 35.5-67.9% vs. 86.7%, 95%CI, 77.1%-97.5%, respectively) (p = 0.0000) and a significantly lower overall survival at 120 months (67.1%, 95%CI, 51.387.6 vs. 94.4%, 95%CI, 86.9-100%, respectively) (p = 0.003) than those without cirrhosis at presentation.Conclusion. Patients with type 1 autoimmune hepatitis and cirrhosis at presentation have a lower survival than those without cirrhosis despite a similar response to treatment

Single-dose Universal Hepatitis A Immunization in One-year-old Children in Argentina: High Prevalence of Protective Antibodies up to 9 Years After Vaccination

Fil: Urueña, Analía. Dirección Nacional de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, C.A.B.A.; Argentina.Fil: González, Jorge E. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Rearte, Analía. Dirección Nacional de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, C.A.B.A.; Argentina.Fil: Pérez Carrega, María Eugenia. Dirección Nacional de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, C.A.B.A.; Argentina.Fil: Calli Flores, Rogelio. Dirección de Epidemiología del Ministerio de Salud Pública de la Provincia de Tucumán, Tucumán; Argentina.Fil: Pagani, María F. Servicio de Gastroenterología. Hospital del Niño Jesús de Tucumán, Tucumán; Argentina.Fil: Uboldi, Andrea. Programa Ampliado de Inmunizaciones, Ministerio de Salud de la Provincia de Santa Fe, Santa Fe; Argentina.Fil: Vicentín, Rosalía. Servicio de Gastroenterología, Hospital de Niños Dr. Orlando Alassia, Santa Fe; Argentina.Fil: Caglio, Patricia. Hospital Nacional Prof. Dr. Alejandro Posadas, Provincia de Buenos Aires; Argentina.Fil: Cañero-Velasco, María C. Hospital de Niños de San Justo, Provincia de Buenos Aires; Argentina.Fil: Gentile, Angela. Hospital de Niños Ricardo Gutiérrez, C.A.B.A.; Argentina.Fil: Ramonet, Margarita. Comisión Nacional de Hepatología, Sociedad Argentina de pediatría, C.A.B.A.; Argentina.Fil: Vizzotti, Carla. Dirección Nacional de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, C.A.B.A.; Argentina.Single-dose hepatitis A virus (HAV) vaccination was implemented in all Argentinean children 12 months of age in 2005. Previous studies demonstrated high prevalence of protective antibody response 4 years after single-dose vaccination. This study assessed long-term seroprotection against HAV after vaccination